Mitotic disruption induced by TTFields leads to immunogenic cell death, causing an influx of T cells into tumors. This suggests a potential synergy between TTFields and immunotherapeutic approaches such as checkpoint blockade and personalized cancer vaccines. Dr. Rubinsteyn is set to assess TTField-induced neoantigen formation and the impact of the anti-PD-1 (or anti-PD-L1)/TTField combination on tumor infiltrating T cells. In pursuit of these aims, he plans to interrogate the genomic landscape of TTFields-induced mutations and the functionality of neoantigen specific T cells.
|Effective start/end date||1/01/19 → …|
- American Association for Cancer Research
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.